Navigation Links
ImaginAb, Inc. Concludes Licensing Agreement With UCLA for Novel Radiochemistry Technology
Date:4/18/2011

LOS ANGELES, April 18, 2011 /PRNewswire/ -- ImaginAb, Inc. and the University of California, Los Angeles (UCLA) have concluded a technology licensing agreement relating to novel fluorine chemistry for the rapid and robust labeling of proteins, peptides and biomolecules for diagnostic imaging with Positron Emission Tomography (PET).

"We are pleased that ImaginAb has expanded its technology portfolio and recognized the cutting-edge work being developed by the Crump Institute," said Dr. Claire Wake, Director, at the university's Office of Intellectual Property and Industry Sponsored Research (OIP-ISR).

"UCLA is truly a world leader in technologies related to PET, from Molecular and Medical Pharmacology department chair Dr. Michael Phelps' pioneering of the field some thirty years ago to the incredible multi-disciplinary innovation occurring there today," said Dr. Christian Behrenbruch, CEO of ImaginAb. "This technology will become an important part of ImaginAb's strategy to combine the readily available and low-cost supply of F-18 from existing cyclotron networks with ImaginAb's rapid development of targeted molecular imaging agents based on antibody fragments and other small protein scaffolds."

The licensed technology originates from the UCLA's Crump Institute for Molecular Imaging through research sponsored by the U.S. Department of Energy. The agreement grants exclusivity to ImaginAb for antibodies and antibody fragments.

About ImaginAb

Founded in 2007 by UCLA faculty members Dr. Robert Reiter, Professor of Urology and Molecular Biology, Dr. Anna Wu, Professor, Molecular & Medical Pharmacology and then-faculty member Dr. Behrenbruch, ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications. The company has a significant pipeline of clinical products in development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT and optical imaging systems, and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products. For more information about ImaginAb, visit www.imaginab.com.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.
Anna Wu
https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=91513


'/>"/>
SOURCE ImaginAb, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. ImaginAb, Inc. and BZL Biologics, LLC Conclude Licensing Agreement for Imaging Rights to huJ591/Prostate-Specific Membrane Antigen (PSMA)
2. ImaginAb, Inc. and GE Imanet Sign Agreement to Provide Customized, Targeted PET Imaging Agents for Drug Research
3. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
4. Energy technologies not enough to sufficiently reduce carbon emissions, NYUs Hoffert concludes
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
7. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
10. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
11. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:4/13/2016)... , April 13, 2016  IMPOWER physicians supporting Medicaid ... setting a new clinical standard in telehealth thanks to ... leveraging the higi platform, IMPOWER patients can routinely track ... and body mass index, and, when they opt in, ... convenient visit to a local retail location at no ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):